vlx-1005
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 24, 2021 (NCT04783545)
Timeline
Indications
Mechanism of action
- Arachidonate 12-lipoxygenaseINHIBITOR
ALOX12 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1cccc(CNc2ccc(S(=O)(=O)Nc3nc4ccccc4s3)cc2)c1O- Mol. weight
- 441.53 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3113165 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05785819 | Phase 2 | Sep 26, 2023 | Duke University, Veralox Therapeutics |
| NCT05325346 | Phase 1 | Mar 7, 2022 | Celerion, Veralox Therapeutics |
| NCT04783545 | Phase 1 | Mar 24, 2021 | Celerion, Veralox Therapeutics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Veralox Therapeutics | For profit | 3 | 3 | 2 | 2021 |
| Celerion | For profit | 2 | 0 | 1 | 2021 |
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1